Navigation Links
PAREXEL Opens New Office in Japan and Further Strengthens Leading Presence in Asia/Pacific Region
Date:10/4/2010

BOSTON, Oct. 4 /PRNewswire/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has opened a new office in Nagoya, Japan to support a growing demand for a broad range of clinical development and regulatory consulting capabilities in the country and throughout the Asia/Pacific region. This office further expands PAREXEL's presence in Japan, which includes locations in Tokyo and Kobe. PAREXEL now has 18 offices throughout important biopharmaceutical centers in the Asia/Pacific region, which in addition to Japan also includes a strong presence in Australia, China, India, Indonesia, Malaysia, the Philippines, Singapore, South Korea, Taiwan, and Thailand.

"Japan continues to maintain its position as the second largest pharmaceutical market globally, and is among the most mature markets within the Asia/Pacific region. Japan is attractive to our worldwide client base for inclusion in global studies not only for its market potential but also for its high quality data, advanced technologies, and large pool of well-trained professionals. Clients have continued to rely on PAREXEL's in-depth expertise in Japan as well as our fully-integrated, harmonized global processes and standards to support their programs," said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International.

"The opening of our office in Nagoya builds on our established presence and long-term, ongoing commitment to Japan. PAREXEL's expansion in Japan allows us to further assist locally-based clients with regional and global market access opportunities. Our regulatory and clinical experts are supporting what we call 'Japan plus Asia' studies since recent regulatory changes allow for inclusion of non-Japanese data for registration purposes. We are also supporting Japan-based biopharmaceutical companies with simultaneous global clinical studies across a broad range of therapeutic areas, and providing eClinical solutions to accelerate the clinical development process," said Mr. von Rickenbach.

When PAREXEL was founded 28 years ago, the Company began helping clients based in Japan with U.S. regulatory filings. In 1995, PAREXEL opened its first office in Japan in Kobe. Since then, PAREXEL has continued to expand its work with Japanese companies to assist them with the development and commercialization of their products.

The opening of PAREXEL's latest office in the Asia/Pacific region, where the Company has had a presence for approximately 15 years, reinforces its long-term commitment to providing clients with a high level of service and quality clinical development solutions in this geography. Today, PAREXEL is one of the area's leading providers of biopharmaceutical services, helping clients design drug development programs and conduct studies regionally and internationally. PAREXEL experts support biopharmaceutical companies in accessing diverse patient populations, navigating regulatory issues, identifying investigators, and ensuring data quality throughout the Asia/Pacific region.

For information about PAREXEL's global clinical research services, visit http://www.parexel.com/services-and-capabilities/clinical-research/. For additional information about PAREXEL's capabilities in Asia and other emerging regions, and to access the white paper entitled "Country-by-country insights into the key challenges and opportunities for development in the Asia/Pacific region" visit http://www.parexel.com/business-challenges/emerging-regions/.

About PAREXEL International PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 54 countries around the world, and has approximately 9,720 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended June 30, 2010 as filed with the SEC on August 27, 2010, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public RelationsPAREXEL InternationalTel: +781-434-4409Email: Jennifer.Baird@PAREXEL.comKim Baker/Gene CarozzaPAN CommunicationsTel: + 978-474-1900Email: PAREXEL@pancomm.com
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
2. PAREXEL Expands Global Clinical Pharmacology Capabilities
3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
4. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
5. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
7. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
8. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
9. PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference
10. PAREXEL Introduces Temperature Recording Solution for Study Drug Transportation, Bringing More Efficiency to Clinical Supply Chain
11. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... May 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it is teaming ... STI Technologies Limited to lower diabetes healthcare costs in ... innoviCares card, which is available throughout all provinces and ... will be eligible for additional savings when shopping for ...
(Date:5/3/2017)... 2017 A Catheterization Laboratory is an ... facility. Commonly referred to as cath lab, this ... imaging technology to give physicians visual access to ... spaces, a team of physicians perform life-saving procedures ... intervention, congenital heart defect closure, stenotic heart valves, ...
(Date:5/3/2017)... Pa. , May 3, 2017  West ... in innovative solutions for injectable drug administration, announced ... Scientific Affairs and Technical Services, and Diane ... workshops and offering presentations focused on West,s expertise ... injectable products, as well as providing commentary on ...
Breaking Medicine Technology:
(Date:5/26/2017)... MN (PRWEB) , ... May 26, 2017 , ... A ... U.S. states with the healthiest seniors are located in the Midwest. With the average ... more and more people are concerned with both the quality and affordability of where ...
(Date:5/26/2017)... , ... May 26, 2017 , ... After raising nearly ... Top gadget will continue to be available at a discounted crowdfunding price on ... stress wherever they are, I also wanted to bring a fidget toy to the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing ... blog post on insurance options. If a Bay Area patient has to search for ... and money. Visiting an in-network provider for a second opinion can ensure a patient ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “Just What Happened in the Garden of Eden”: ... the Garden of Eden” is the creation of published author, Penelope Colt, mother, trader, horse ... family moved to NYC when she was three. At six, they moved to Dayton, ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, success ... appropriate instruments for research and understanding the basic principles that were designed to ... on innovations in stereo microscopy for brightfield and fluorescence typically used in laboratories ...
Breaking Medicine News(10 mins):